FORM PTO-1449 (REV. 7-85)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ENEQRMATION DISCLOSURE CITATION

everal sheets if necessary)

ATTY. DOCKET NO. 4-31394B APPLICATION NO. 10/826,106 APPLICANT Ronald Edward Steele FILING DATE APRIL 15, 2004

Group 1614

EXAMINER L.A. ROYDS

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
ian	AA	4,997,948	3/5/91	Zask et al.	548	183	10/27/89
LAR	AB	5,057,521	10/15/91	Hausler et al.	514	300	9/26/89
MAL	AC	5,252,565	10/12/93	Peet et al.	514	177	9/6/91
LAL	AD	5,906,987	5/25/99	Chwalisz et al.	514	177	3/10/97
WAR	AE	5,972,921	10/26/99	Santti et al.	514	177	12/12/97
MAR	AF	4,889,861	12/1/89	Browne, Leslie J.	514	300	11/13/87
VAL	AG	5,972,921	10/1/99	Santti et al.	514	177	12/12/97
NAR	АН	6,653,306	11/1/03	Alexander et al.	514	234.5	1/9/97
	Al	_	_	_	-	_	-
_	AJ		- .	_		_	
_	AK	_	-	_	_	_	_
-	AL	-	-	_	_	_	

FOREIGN PATENT DOCUMENTS

	,	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
LAR	АМ	WO 00/02543	1/20/00	PCT	-			
LARE	AN	WO 98/03180	1/29/98	PCT		_		
WAL	AO	WO 99/45779	9/16/99	PCT		_		
Line	AP	WO01/76574 A2	10/18/01	PCT				
	AQ	_	_					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

WAR	AR	Masato et al., "AlGaAs/GaAs Double-Doped Quantum-Well HEMTs for Low Distortion Amplifier", Extended Abstracts of the 1993 International Conference on Solid State Devices and Materials, Japan Soc. Appl. Physics, Tokyo, Japan, pp. 715-717 (1993).
		Chem. Abstracts, File Registery Abstract for Compound RN # 135070-05-02 (2004).
PW	AS	<u>/</u>
		Derwent Abstract, FR 2,766,821, 2/5/99 - Sanofi SA
1200	AT	Kad Olaman
EXAMIN	ER	DATE CONSIDERED 29 AVECUST 2000
	-	
*EXAMINE	R: \	hitial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in

conformance and riot considered. Include a copy of this form with the next communication to applicant.

Sheet 2 of 2

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 4-31394B APPLICATION NO. 10/826,106 APPLICANT Ronald Edward Steele FILING DATE APRIL 15, 2004

Group 1614

EXAMINER L.A. ROYDS

EXAMINER OTHER DOCUMENTS (Including Author, Title, Date, Perlinent pages, Etc.) Faggiotto and Paoletti. "Statins and Blockers of the Renin-Angiotensin System. Vascular Protection Beyond Their Primary Mode of Action". Hypertension, Vol. 34, Part II, pp. 987-996 (1999). LAR ΑU Hagman et al., Journal of Cardiovascular Pharmacology, vol. 29, No. 4, pp. 444-450 (1997) ΑV LPR Harrison's Principles of Internal Medicine, 9th ed., Isselbacher et al. (eds), published 1980, pages 1035, 1036 and 1299. AW LAR Harrison's Prinicples of Internal Medicine, 13th ed. Isselbacher et al., (eds), Vol. 1, published 1994. page 986 AX MAL Jeremic et al., "Effects of a New Angiotensin-Converting Enzyme Inhibitor (Idrapril) in rats with left inc AY Ventricular Dysfunction After Myocardial Infarction", J. Cardiovasc. Pharmacol., Vol. 27, No. 3, pp. 347-354 (1996) Johnston et al., "Enzyme-Activated Inhibitors of Steroidal Hydroxylases", J. Steroid Biochem. Molec. biol. Vol. 52, No. 1, pp. 17-34 (1995) ΑZ *NAR* Makino et al., "Regression of Hypertrophy After Myocardial Infarction is Produc4ed by the Chronic BA Blockade of Angiotensin Type 1 Receptor in Rats"J. Mol. Cello. Cardiol., Vol. 28, pp. 507-517 LANC Maxfield et al., Diabetologia, vol. 36, no. 12, pp 1230-1237 (1993) XP001053448. BB AR Patent Abstract of Japan, vol. 1997, no. 7, Yamanouchi, JP 09071586A, July 31, 1997 XP000409466 SA BC The Merck Index, Twelfth Edition, Budavari, editor, Merck & Co. Inc., Whitehouse Station, NJ, p PX 105 [667. Anastrozole - Japan Abstract]: p 666 [3969. Fadrozole] (1996) BD Viigimaa et al., Cardiovascular Drugs and Therapy, vol. 14, no. 4, pp 447-449 (2000) XP001053452 BE LARE **BF** BG **EXAMINER** DATE CONSIDERED 29 AVGW

*EXAMINER: Initial Difference considered, whether of not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

PATENT AND TRADEMARK OFF

everal sheets if necessary)

DEC 2 0 7005

ATTY. DOCKET NO. 4-31394B APPLICATION NO. 10/826,106 APPLICANT Ronald Edward Steele **FILING DATE APRIL 15, 2004**

EXAMINER LARDYDS

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
IAR	AA	5,795,909	8/18/98	Shashoua et al.	514	449	5/22/96
1	AB	_	_		_		_
<u> </u>	AC				_		_
_	AD	_	_				
	ΑE	_	_	_			_
<u> </u>	AF		_	_	_	_	_
_	AG	_		-			
	AH	-	_	_			_
	Al	_	-	_			_
	AJ	_					

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
LAR	AK	WO 96/40257	12/19/96	WIPO		-		
LAR	AL	WO 96/40258	12/19/98	WIPO	_	_		
	AM	_	_	_		_		<u> </u>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

LAR	AN	Beers et al., The Merck Manual of Diagnosis and Therapy, Seventeenth Edition, pp 1628-1693 and 1840-1848
LAR	AO	Results for Registry No. 135070-05-2 STN Registry File, Retrieved from STN 2005-06-17 (1 page)
KAR	АР	Furet et al., Aromatase Inhibitors: Synthesis, Biological Activity and Binding Mode of Azole-Type Compounds, Journal of Medicinal Chemistry, No. 36: pp 1393-1400 (1993)
LAR	AQ	Trunet et al., The Effects of Fadrozole Hydrochloride on Aldosterone Secretion in Healthy Male Subjects, Journal of Clinical Endocrinology and Metabolism, 74(3) pp 571-576 (1992)
LAC	AR	Haeusler et al., Evidence that corticosterone is not an obligatory Intermediate in Aldosterone biosynthesis in the Rat Adrenal. Journal of steroid Biochemistry, 34 (1-6) pp. 567-570 (1989).
FYAMIN	ED \/	DATE CONSIDERED